Mammalian target of rapamycin and caspase inhibitors in polycystic kidney disease

Clinical Journal of the American Society of Nephrology

Volumn 3, Issue 4, 2008, Pages 1219-1226

  Edelstein, Charles L ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CYSTEINE PROTEINASE INHIBITOR; MTOR PROTEIN, HUMAN; MTOR PROTEIN, MOUSE; MTOR PROTEIN, RAT; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; TARGET OF RAPAMYCIN KINASE;

ANIMAL; APOPTOSIS; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; HUMAN; KIDNEY; KIDNEY POLYCYSTIC DISEASE; METABOLISM; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; APOPTOSIS; CASPASES; CELL PROLIFERATION; CYSTEINE PROTEINASE INHIBITORS; HUMANS; KIDNEY; POLYCYSTIC KIDNEY, AUTOSOMAL RECESSIVE; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 49149122236     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.05611207     Document Type: Review

References (65)

1. Ecder T, Fick-Brosnahan G, Schrier RW: Polycystic kidney disease. In: Diseases of the Kidney and Urinary Tract, Vol. 2, 8th Ed., edited by Schrier RW, Philadelphia, Lippincott Williams & Wilkins, 2007, pp 502-539
2. Wilson PD: Polycystic kidney disease. N Engl J Med 350: 151-164, 2004
3. Fingar DC, Blenis J: Target of rapamycin (TOR): An integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23: 3151-3171, 2004
4. Wullschleger S, Loewith R, Hall MN: TOR signaling in growth and metabolism. Cell 124: 471-484, 2006
5. Bhaskar PT, Hay N: The two TORCs and Akt. Dev Cell 12: 487-502, 2007
6. Thedieck K, Polak P, Kim ML, Molle KD, Cohen A, Jemo P, Arrieumerlou C, Hall MN: PRAS40 and PRR5-like protein are new mTOR interactors that regulate apoptosis. Plos ONE 2: e1217, 2007
7. Lee L, Sudentas P, Donohue B, Asrican K, Worku A, Walker V, Sun Y, Schmidt K, Albert MS, El-Hashemite N, Lader AS, Onda H, Zhang H, Kwiatkowski DJ, Dabora SL: Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models. Genes Chromosomes Cancer 42: 213-227, 2005
8. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, Salisbury S, Franz DN: Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 358: 140 -151, 2008
9. Mei C, Mao Z, Shen X, Wang W, Dai B, Tang B, Wu Y, Cao Y, Zhang S, Zhao H, Sun T: Role of keratinocyte growth factor in the pathogenesis of autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 20: 2368-2375, 2005
10. Gattone VH, Ricker JL, Trambaugh CM, Klein RM: Multiorgan mRNA misexpression in murine autosomal recessive polycystic kidney disease. Kidney Int 62: 1560-1569, 2002
11. Hashemolhosseini S, Nagamine Y, Morley SJ, Desrivieres S, Mercep L, Ferrari S: Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem 273: 14424-14429, 1998
12. Bukanov NO, Smith LA, Klinger KW, Ledbetter SR, Ibraghimov-Beskrovnaya O: Long lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. Nature 444: 949-952, 2006
13. Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, Bauerlein R, Zlotchenko E, Scrimgeour A, Lawrence JC, Glass DJ, Yancopoulos GD: Akt/ mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol 3: 1014-1019, 2001
14. Chen JK, Chen J, Neilson EG, Harris RC: Role of mTOR signaling in compensatory renal hypertrophy. J Am Soc Nephrol 16: 1384-1391, 2005
15. Nakamura T, Ebihara I, Nagaoka I, Tomino Y, Nagao S, Takahashi H, Koide H: Growth factor gene expression in kidney of murine polycystic kidney disease. J Am Soc Nephrol 3: 1378-1386, 1993
16. Aukema HM, Housini I: Dietary soy protein effects on disease and IGF-I in male and female Han:SPRD-cy rats. Kidney Int 59: 52-61, 2001
17. Mehls O, Irzynjec T, Ritz E, Eden S, Kovacs G, Klaus G, Floege J, Mall G: Effects of rhGH and rhIGF-1 on renal growth and morphology. Kidney Int 44: 1251-1258, 1993
18. Alvaro D, Mancino MG, Onori P, Franchitto A, Alpini G, Francis H, Glaser S, Gaudio E: Estrogens and the pathophysiology of the biliary tree. World J Gastroenterol 12: 3537-3545, 2006
19. Sweeney WE, Chen Y, Nakanishi K, Frost P, Avner ED: Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor. Kidney Int 57: 33-40, 2000
20. Du J, Wilson PD: Abnormal polarization of EGF receptors and autocrine stimulation of cyst epithelial growth in human ADPKD. Am J Physiol 269: C487-C495, 1995
21. Takaoka M, Smith CE, Mashiba MK, Okawa T, Andl CD, El Deiry WS, Nakagawa H: EGF-mediated regulation of IGFBP-3 determines esophageal epithelial cellular response to IGF-I. Am J Physiol Gastrointest Liver Physiol 290: G404-G416, 2006
22. Nishio S, Hatano M, Nagata M, Horie S, Koike T, Tokuhisa T, Mochizuki T: Pkd1 regulates immortalized proliferation of renal tubular epithelial cells through p53 induction and JNK activation. J Clin Invest 115: 910-918, 2005
23. Wu M, Wahl PR, Le Hir M, Wackerle-Men Y, Wuthrich RP, Serra AL: Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease. Kidney Blood Press Res 30: 253-259, 2007
24. Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N, Flask CA, Novick AC, Goldfarb DA, Kramer-Zucker A, Walz G, Piontek KB, Germino GG, Weimbs T: The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S A 103: 5466-5471, 2006
25. Wahl PR, Serra AL, Le Hir M, Molle KD, Hall MN, Wuthrich RP: Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant 21: 598-604, 2006
26. Huang S, Houghton PJ: Targeting mTOR signaling for cancer therapy, Curr Opin Pharmacol 3: 371-377, 2003
27. Tao Y, Kim J, Schrier RW, Edelstein CL: Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease (PKD). J Am Soc Nephrol 16: 46-51, 2005
28. Trudel M, Barisoni L, Lanoix J, D'Agati V: Polycystic kidney disease in SBM transgenic mice: Role of c-myc in disease induction and progression. Am J Pathol 152: 219-229, 1998
29. Ramasubbu K, Gretz N, Bachmann S: Increased epithelial cell proliferation and abnormal extracellular matrix in rat polycystic kidney disease. J Am Soc Nephrol 9: 937-945, 1998
30. Tejani A, Alexander S, Ettenger R, Lerner G, Zimmerman J, Kohaut E, Briscoe DM: Safety and pharmacokinetics of ascending single doses of sirolimus (Rapamune, rapamycin) in pediatric patients with stable chronic renal failure undergoing dialysis. Pediatr Transplant 8: 151-160, 2004
31. Ettenger RB, Grimm EM: Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients. Am J Kidney Dis 38: S22-S28, 2001
32. Qian Q, Hui D, King BF, Kumar S, Dean PG, Cosio FG, Torres VE: Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol 19: 631-638, 2008
33. Zhou XJ, Kukes G: Pathogenesis of autosomal dominant polycystic kidney disease: role of apoptosis. Diagn Mol Pathol 7: 65-68, 1998
34. Lanoix J, D'Agati V, Szabolcs M, Trudel M: Dysregulation of cellular proliferation and apoptosis mediates human autosomal dominant polycystic kidney disease (ADPKD). Oncogene 13: 1153-1160, 1996
35. Woo D: Apoptosis and loss of renal tissue in polycystic kidney diseases. N Engl J Med 333: 18-25, 1995
36. Lager DJ, Qian Q, Bengal RJ, Ishibashi M, Torres VE: The pck rat: A new model that resembles human autosomal dominant polycystic kidney and liver disease. Kidney Int 59: 126-136, 2001
37. Nauli SM, Alenghat FJ, Luo Y, Williams E, Vassilev P, Li X, Elia AE, Lu W, Brown EM, Quinn SJ, Ingber DE, Zhou J: Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat Genet 33: 129-137, 2003
38. Winyard PJ, Nauta J, Lirenman DS, Hardman P, Sams VR, Risdon RA, Woolf AS: Deregulation of cell survival in cystic and dysplastic renal development. Kidney Int 49: 135-146, 1996
39. Moser M, Pscherer A, Roth C, Becker J, Mucher G, Zerres K, Dixkens C, Weis J, Guay-Woodford L, Buettner R, Fassler R: Enhanced apoptotic cell death of renal epithelial cells in mice lacking transcription factor AP-2beta. Genes Dev 11: 1938-1948, 1997
40. Veis DJ, Sorenson CM, Shutter JR, Korsmeyer SJ: Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 75: 229-240, 1993
41. Ali SM, Wong VY, Kikly K, Fredrickson TA, Keller PM, DeWolf WE Jr, Lee D, Brooks DP: Apoptosis in polycystic kidney disease: Involvement of caspases. Am J Physiol Regul Integr Comp Physiol 278: R763-R769, 2000
42. Melnikov VY, Ecder T, Fantuzzi G, Siegmund B, Lucia MS, Dinarello CA, Schrier RW, Edelstein CL: Impaired IL-18 processing protects caspase-1-deficient mice from ischemic acute renal failure. J Clin Invest 107: 1145-1152, 2001
43. Tao Y, Kim J, Stanley M, He Z, Faubel SG, Schrier RW, Edelstein CL: Pathways of caspase-mediated apoptosis in autosomal dominant polycystic kidney disease (ADPKD). Kidney Int 67: 909-919, 2004
44. Edelstein CL: What is the role of tubular epithelial cell apoptosis in polycystic kidney disease (PKD)? Cell Cycle 4: e141-e145, 2005
45. Trudel M, Lanoix J, Barisoni L, Blouin MJ, Desforges M, L'Italien C, D'Agati VD: C-MYC-induced apoptosis in polycystic kidney disease is Bcl-2 and p53 independent. J Exp Med 186: 1873-1884, 1997
46. Sorenson CM, Padanilam BJ, Hammerman MR: Abnormal postpartum renal development and cystogenesis in the bcl-2 (-/-) mouse. Am J Physiol 271: F184-F193, 1996
47. Ogborn MR, Bankovic-Calic N, Shoesmith C, Buist R, Peeling J: Soy protein modification of rat polycystic kidney disease. Am J Physiol 274: F541-F549, 1998
48. Tomobe K, Philbrick DJ, Ogborn MR, Takahashi H, Holub BJ: Effect of dietary soy protein and genistein on disease progression in mice with polycystic kidney disease. Am J Kidney Dis 31: 55-61, 1998
49. Aukema HM, Housini I, Rawling JM: Dietary soy protein effects on inherited polycystic kidney disease are influenced by gender and protein level. J Am Soc Nephrol 10: 300-308, 1999
50. Philbrick DJ, Bureau DP, Collins FW, Holub BJ: Evidence that soyasaponin Bb retards disease progression in a murine model of polycystic kidney disease. Kidney Int 63: 1230-1239, 2003
51. Torres VE: Apoptosis in cystogenesis: Hands on or hands off? Kidney Int 55: 334-335, 1999
52. Lin HH, Yang TP, Jiang ST, Yang HY, Tang MJ: Bcl-2 overexpression prevents apoptosis-induced Madin-Darby canine kidney simple epithelial cyst formation. Kidney Int 55: 168-178, 1999
53. Boletta A, Qian F, Onuchic LF, Bhunia AK, Phakdeekitcharoen B, Hanaoka K, Guggino W, Monaco L, Germino GG: Polycystin-1, the gene product of PKD1, induces resistance to apoptosis and spontaneous tubulogenesis in MDCK cells. Mol Cell 6: 1267-1273, 2000
54. Mai W, Chen D, Ding T, Kim I, Park S, Cho SY, Chu JS Liang D, Wang N, Wu D, Li S, Zhao P, Zent R, Wu G: Inhibition of Pkhd1 impairs tubulomorphogenesis of cultured IMCD cells. Mol Biol Cell 16: 4398-4409, 2005
55. Tao Y, Zafar I, Kim J, Schrier RW, Edelstein CL: Caspase-3 gene deletion prolongs survival in polycystic kidney disease. J Am Soc Nephrol 19: 749-755, 2008
56. Ostrom L, Tang MJ, Gruss P, Dressler GR: Reduced Pax2 gene dosage increases apoptosis and slows the progression of renal cystic disease. Dev Biol 219: 250-258, 2000
57. Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ: p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci U S A 98: 9666-9670, 2001
58. Castedo M, Ferri KF, Kroemer G: Mammalian target of rapamycin (mTOR): Pro- and anti-apoptotic. Cell Death Differ 9: 99-100, 2002
59. Thyrell L, Hjortsberg L, Arulampalam V, Panaretakis T, Uhles S, Dagnell M, Zhivotovsky B, Leibiger I, Grander D, Pokrovskaja K: Interferon alpha-induced apoptosis in tumor cells is mediated through the phosphoinositide 3-kinase/mammalian target of rapamycin signaling pathway. J Biol Chem 279: 24152-24162, 2004
60. Calastretti A, Rancati F, Ceriani MC, Asnaghi L, Canti G, Nicolin A: Rapamycin increases the cellular concentration of the BCL-2 protein and exerts an anti-apoptotic effect. Eur J Cancer 37: 2121-2128, 2001
61. Castedo M, Ferri KF, Blanco J, Roumier T, Larochette N, Barretina J, Amendola A, Nardacci R, Metivier D, Este JA, Piacentini M, Kroemer G: Human immunodeficiency virus 1 envelope glycoprotein complex-induced apoptosis involves mammalian target of rapamycin/ FKBP12-rapamycin-associated protein-mediated p53 phosphorylation. J Exp Med 194: 1097-1110, 2001
62. Ferri KF, Jacotot E, Blanco J, Este JA, Zamzami N, Susin SA, Xie Z, Brothers G, Reed JC, Penninger JM, Kroemer G: Apoptosis control in syncytia induced by the HIV type 1-envelope glycoprotein complex: Role of mitochondria and caspases. J Exp Med 192: 1081-1092, 2000
63. Tao Y, Kim Y, Heasley L, Schrier RW, Edelstein CL: Rapamycin, mammalian target of rapamycin (mTOR) signaling and apoptosis in the Han:SPRD rat model of polycystic kidney disease (PKD) [Abstract]. J Am Soc Nephrol 16: 161A, 2005
64. Hsu YC, Chern JJ, Cai Y, Liu M, Choi KW: Drosophila TCTP is essential for growth and proliferation through regulation of dRheb GTPase. Nature 445: 785-788, 2007
65. Adams JM, Cory S: The Bcl-2 protein family: Arbiters of cell survival. Science 281: 1322-1326, 1998